Harvey Capital Management Inc. Buys 249,790 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST)

Harvey Capital Management Inc. grew its holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 1,419.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 267,390 shares of the company's stock after purchasing an additional 249,790 shares during the period. Harvey Capital Management Inc. owned about 0.29% of Aquestive Therapeutics worth $952,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Financial Advocates Investment Management increased its holdings in Aquestive Therapeutics by 14.7% in the third quarter. Financial Advocates Investment Management now owns 39,000 shares of the company's stock worth $194,000 after buying an additional 5,000 shares during the last quarter. nVerses Capital LLC bought a new stake in shares of Aquestive Therapeutics in the third quarter valued at approximately $28,000. SG Americas Securities LLC lifted its position in Aquestive Therapeutics by 28.7% in the fourth quarter. SG Americas Securities LLC now owns 32,966 shares of the company's stock worth $117,000 after purchasing an additional 7,347 shares during the period. Charles Schwab Investment Management Inc. lifted its position in Aquestive Therapeutics by 4.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 203,540 shares of the company's stock worth $1,014,000 after purchasing an additional 9,268 shares during the period. Finally, BNP Paribas Financial Markets lifted its position in Aquestive Therapeutics by 252.2% in the third quarter. BNP Paribas Financial Markets now owns 18,826 shares of the company's stock worth $94,000 after purchasing an additional 13,481 shares during the period. Institutional investors and hedge funds own 32.45% of the company's stock.

Aquestive Therapeutics Trading Down 4.3 %

Shares of NASDAQ:AQST traded down $0.15 during trading on Friday, hitting $3.32. 1,531,790 shares of the company's stock traded hands, compared to its average volume of 1,180,782. Aquestive Therapeutics, Inc. has a 52 week low of $2.24 and a 52 week high of $6.23. The company has a market cap of $302.72 million, a price-to-earnings ratio of -7.38 and a beta of 2.67. The company has a 50-day moving average price of $3.33 and a 200-day moving average price of $4.19.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on AQST. Cantor Fitzgerald began coverage on Aquestive Therapeutics in a research note on Tuesday, December 17th. They set an "overweight" rating and a $17.00 price objective for the company. HC Wainwright reiterated a "buy" rating and issued a $10.00 price target on shares of Aquestive Therapeutics in a report on Friday, December 20th. Finally, Leerink Partners raised their price target on Aquestive Therapeutics from $12.00 to $13.00 and gave the company an "outperform" rating in a report on Friday, October 25th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Aquestive Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $11.00.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.